Back to results
US 2013/0210796 A1Published application
Tetrazole compounds as calcium channel blockers
AssigneeConvergence Pharmaceuticals Limited
InventorsPaul Beswick, Robert James Gleave, Shuji Hachisu, Sadie Vile, Nicholas Bertheleme, Simon E. Ward
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial. Formula (I) wherein A is: (II) or (III) wherein A is
Claims24
A compound of formula (I), or a salt thereof:
- wherein
- A is
- R1 is hydrogen, methyl or chloro;
- R2 is hydrogen, trifluoromethyl, trifluoromethoxy, chloro or cyano;
- R3 is hydrogen, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, chloro, bromo, —S—CH3, —SO2—C1-3alkyl or —SF5;
- R4 is hydrogen, trifluoromethyl, trifluoromethoxy, chloro or cyano;
- R5 is hydrogen, methyl or chloro;
- wherein at least one of R1, R2, R3, R4 or R5 is a group other than hydrogen;
- X is —CH2—, —CH2—CH2— or —CH(CH3)—;
- wherein when R1 is methyl, R5 is hydrogen or chloro, and when R5 is methyl, R1 is hydrogen or chloro;
- wherein when R2 is chloro, R4 is hydrogen, trifluoromethyl, trifluoromethoxy or cyano, and when R4 is chloro, R2 is hydrogen, trifluoromethyl, trifluoromethoxy or cyano;
- R6 is hydrogen and R7 is C1-5 alkyl or C3-6cycloalkyl;
- or R6 and R7 together with the nitrogen atom to which they are attached form a saturated ring system B, where B is selected from
- a) a 4 to 7 membered monocyclic heterocyclic ring,
- b) a 5 to 10 membered fused bicyclic ring system;
- c) a bridged 4 to 7 membered monocyclic heterocyclic ring system;
- and
- d) a 7 to 11 membered spiro ring system;
- which ring system B is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, oxo, C1-3alkyl, cyano, —SO2—C1-3alkyl, C1-3haloalkyl and —CO—C1-3alkyl;
- with the proviso that the compound is not 4-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}morpholine, 4-({1-[3-(trifluoromethyl)phenyl]-1H-tetrazol-5-yl}methyl)morpholine hydrochloride, 4-({1-[3-(trifluoromethyl)phenyl]-1H-tetrazol-5-yl}methyl)morpholine, 4-{[1-(3,4-dichlorophenyl)-1H-tetrazol-5-yl]methyl}morpholine, 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}-4-(methylsulfonyl)piperazine, 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}-4-(propylsulfonyl)piperazine;
- 1-{[1-(3,4-dichlorophenyl)-1H-tetrazol-5-yl]methyl}piperidine;
- 4-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}morpholine;
- 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}-4-methylpiperidine;
- 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}piperidine;
- 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}-4-(ethylsulfonyl)piperazine;
- 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}-2-methylpiperidine;
- 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}piperazine;
- 1-(4-chlorophenyl)-5-(1-pyrrolidinylmethyl)-1H-tetrazole;
- 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}-4-methylpiperazine or 1-{[1-(4-chlorophenyl)-1H-tetrazol-5-yl]methyl}hexahydro-1H-azepine.
26 more elements
(canceled)
Dependencies are inferred from the claim text.